Nuclivision Funding News- Belgium-based medtech Nuclivision Raises €5M Funding

The funding will help Nuclivision bring its main product, Nuclarity, to market. Nuclarity is an AI-powered software that improves PET scans by making them faster and safer reducing scan time and radiation exposure while keeping image quality high.

Founded in 2022, Nuclivision is part of a new generation of European deeptech startups using AI to improve complex and costly healthcare procedures. Their technology focuses on PET (positron emission tomography) scans, which are often used to detect and treat diseases like cancer and Alzheimer’s.

Read Also - Cloud Capital Secures $7.7M Funding to Put CFOs Back in Control of Cloud Spend

While PET scans are very precise, they require radioactive tracers and long scanning times, which can be expensive and raise health risks. Nuclarity helps solve these problems by using AI to lower the dose and shorten the scan without losing accuracy.

Nuclivision is now in the final steps of getting regulatory approval and plans to launch its product in Europe soon, with a U.S. launch expected later this year.

“Medical imaging is at an inflection point,” said Nuclivision's CEO, Maarten Larmuseau. “With the rapid growth within radiopharma and theranostics, the use of AI and smart software is becoming necessary to handle the increased demand for PET and SPECT scans for conditions such as cancer and Alzheimer's.”

“Nuclivision is uniquely positioned in the field of AI-driven image enhancement for PET scans with the Nuclarity platform. By reducing the amount of time and the amount of costly and harmful radiotracers required for accurate medical imaging, Nuclarity not only reduces the time pressure on nuclear medicine departments but also the cost and harmful environmental and health impact of PET scans,” said Geoffrey D’hondt from Heran Partners.

“The completion of the regulatory approval process marks the beginning of a new growth phase for Nuclivision that is crucial for the actual deployment and impact of their technology,” explained Sven Bakkes, Founding Partner at LUMO Labs.

“We look forward to supporting the founders and the growing team of Nuclivision in this, of course with indispensable growth capital but also with expertise and frameworks in the field of business operations and impact and with opening up our network.”

About Nuclivision

Nuclivision is a Belgian medtech startup using AI to make nuclear imaging better, safer, and easier to access. Their main goal is to help doctors detect diseases like cancer and Alzheimer’s earlier and more safely by improving PET and SPECT scans with smart, efficient software.